Tri Chemical LaboratoriesTri Chemical Laboratories Inc.4369東証プライム化学FY ending Jan 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥25 is left as operating profit. Revenue changed +26.3% from the prior year, operating profit +12.3%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 35.4% | 0.41× | 14.5% | 1.34× | 19.4% |
| 2023 | 35.0% | 0.46× | 16.0% | 1.30× | 20.9% |
| 2024 | 22.0% | 0.35× | 7.7% | 1.23× | 9.5% |
| 2025 | 26.2% | 0.55× | 14.4% | 1.20× | 17.3% |
| 2026 | 23.1% | 0.57× | 13.1% | 1.28× | 16.7% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Jan 2022 | FY ending Jan 2023 | FY ending Jan 2024 | FY ending Jan 2025 | FY ending Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 11,574 | 13,803 | 11,246 | 18,906 | 23,883 |
| Cost of revenue | 6,739 | 8,224 | 7,160 | 10,894 | 14,864 |
| Gross profit | 4,835 | 5,579 | 4,086 | 8,012 | 9,019 |
| SG&A | 1,859 | 2,075 | 2,138 | 2,756 | 3,117 |
| Operating income | 2,976 | 3,505 | 1,948 | 5,256 | 5,902 |
| Pretax income | 5,295 | 6,187 | 3,277 | 6,583 | 7,090 |
| Income tax | 1,200 | 1,354 | 806 | 1,621 | 1,575 |
| Net income attributable to owners | 4,095 | 4,832 | 2,471 | 4,962 | 5,515 |
| Operating margin | 25.7% | 25.4% | 17.3% | 27.8% | 24.7% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Jan 2022 | FY ending Jan 2023 | FY ending Jan 2024 | FY ending Jan 2025 | FY ending Jan 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥8.03B | ¥11.1B | ¥10.5B | ¥9.44B | ¥7.28B |
| Total assets | ¥28.3B | ¥32.1B | ¥31.9B | ¥36.9B | ¥47.3B |
| Net assets | ¥21.3B | ¥25.9B | ¥27.6B | ¥31.6B | ¥36.1B |
| Share capital | ¥3.28B | ¥3.28B | ¥3.28B | ¥3.28B | ¥3.28B |
| Trade receivables | ¥3.06B | ¥3.5B | ¥2.69B | ¥3.63B | ¥4.44B |
| Property, plant and equipment | ¥8.01B | ¥8.37B | ¥9.27B | ¥10.9B | ¥17.2B |
| Intangible assets excluding goodwill | ¥181.4M | ¥134.8M | ¥105.4M | ¥74.2M | ¥89.6M |
| Investment securities | ¥5.54B | ¥4.4B | ¥2.98B | ¥3.92B | ¥6.14B |
| Current assets | ¥14.4B | ¥18.9B | ¥19B | ¥21.5B | ¥23.3B |
| Current liabilities | ¥3.47B | ¥3.68B | ¥2.55B | ¥4.18B | ¥7.6B |
| Long-term borrowings | ¥2.7B | ¥1.91B | ¥1.21B | ¥723M | ¥3.08B |
| Total liabilities | ¥6.97B | ¥6.24B | ¥4.29B | ¥5.36B | ¥11.1B |
| Equity attributable to owners of parent | ¥21.1B | ¥25.3B | ¥26.8B | ¥30.7B | ¥35.1B |
| Retained earnings | ¥14.6B | ¥18.8B | ¥20.3B | ¥24.3B | ¥28.7B |
| Treasury stock | -¥1.7M | -¥2M | -¥2M | -¥2.5M | -¥2.7M |
EDINET (FSA Japan)
有価証券報告書－第48期(2025/02/01－2026/01/31)
EDINET (FSA Japan)
有価証券報告書－第47期(2024/02/01－2025/01/31)
EDINET (FSA Japan)
有価証券報告書－第46期(2023/02/01－2024/01/31)
EDINET (FSA Japan)
有価証券報告書－第45期(2022/02/01－2023/01/31)
EDINET (FSA Japan)
有価証券報告書－第44期(令和3年2月1日－令和4年1月31日)
EDINET (FSA Japan)
有価証券報告書－第43期(令和2年2月1日－令和3年1月31日)
Extracted from XBRL: 48 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.